Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Cancer Research|April 6, 2007
Tumor-released microvesicles as vehicles of immunosuppressionRoberta Valenti, Veronica Huber, Manuela Iero, et al.Cancer Immunology, Immunotherapy : CII|October 13, 2006
Vaccination therapy in prostate cancerAndrea Marrari, Manuela Iero, Lorenzo Pilla, et al.Cancer Immunology, Immunotherapy : CII|November 11, 2008
Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity?Manuela Iero, Paola Filipazzi, Chiara Castelli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2007
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccinePaola Filipazzi, Roberta Valenti, Veronica Huber, et al.Cancer Immunology, Immunotherapy : CII|June 15, 2007
Low TCR avidity and lack of tumor cell recognition in CD8(+) T cells primed with the CEA-analogue CAP1-6D peptideManuela Iero, Paola Squarcina, Pedro Romero, et al.Expert Opinion on Biological Therapy|June 7, 2005
Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control?Licia Rivoltini, Paola Canese, Veronica Huber, et al.Gastroenterology|June 9, 2005
Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escapeVeronica Huber, Stefano Fais, Manuela Iero, et al.International Journal of Cancer|October 31, 2009
pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidityAngelo De Milito, Rossella Canese, Maria Lucia Marino, et al.Cancer Research|May 18, 2012
Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytesArianna Calcinotto, Paola Filipazzi, Matteo Grioni, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 14, 2010
HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapyEmilie Fauquembergue, Olivier Toutirais, David Tougeron, et al.Pageof 2